Companion Sciences, Inc.

Developing treatments for companion animals in the $10 Billion / year animal health market.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Bellport, NY, USA
  • Currency USD
  • Founded November 2015
  • Employees 3
  • Incorporation Type C-corp
  • Website companionsciences.com

Company Summary

We are developing a treatment for anemia in companion animals. Each year approximately 3% of the 74 Million owned cats and 69 Million owned dogs will become anemic. There is no FDA approved drug to treat this condition in cats and dogs, so human medication is used which poses a 20%-50% chance of a fatal immune reaction. Our team are well on the way to developing a drug to treat this condition.

Team

  • Tom Gerbe
    CEO

    Started and ran a number of businesses in various regulated industries. Excels at navigating the quagmire of Government regulation. Experienced in business development, marketing, television production, media relations, software development, contract negotiation, team assembly and management.

  • Peter J. Schatz,
    CSO

    Peter J. Schatz, Ph.D. has 22+ years of drug discovery & development experience in biotech and large pharma environments from early drug discovery through to Phase 3, NDA filing, product approval, and launch. Dr. Schatz most recently was Sr Director, Biology at Affymax, Inc. where he co-invented and helped develop OMONTYS®/peginesatide, a PEGylated peptidic ESA approved in March 2012 for the treatment of anemia in adult kidney dialysis patients.

  • Tom Gerbe

Advisors

  • David Schaffer, Meltzer Lippe
    Lawyer
    Unconfirmed
    Pete Henig - Greenhouse Capital Partners
    Managing Director
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free